Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing
Gaspard Loison,Hélène Bouges Le Royer,Sabrina Marsili,Aurélie Brice,Julien Vintejoux,Malika Yakoubi,Hélène Sirgue,Etienne Chatelut,Marie-Christine Etienne-Grimaldi,Fabienne Thomas
DOI: https://doi.org/10.1515/cclm-2023-1096
2024-01-12
Clinical Chemistry and Laboratory Medicine (CCLM)
Abstract:Research ethics: The local Institutional Review Board deemed the study exempt from review as the samples used in this research come from patients' samples taken in the course of treatment. Patients are clearly informed on their arrival at the institute that, in the absence of any objection on their part, the samples taken may be used for research projects carried out at the institute. We made sure that patients did not object. The samples are pseudoanonymised and the confidentiality of the data is guaranteed. Informed consent: Not applicable. Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission. Competing interests: The authors states no conflict of interest. Research funding: None declared. Data availability: The raw data can be obtained on request from the corresponding author. 1. Ezzeldin, H, Diasio, R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004;4:181–9. https://doi.org/10.3816/ccc.2004.n.018. Search in Google Scholar PubMed 2. Barin-Le Guellec, C, Lafay-Chebassier, C, Ingrand, I, Tournamille, JF, Boudet, A, Lanoue, MC, et al.. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: a real-life evaluation in France. Eur J Cancer 2020;124:37–46. https://doi.org/10.1016/j.ejca.2019.09.028. Search in Google Scholar PubMed 3. Boisdron-Celle, M, Remaud, G, Traore, S, Poirier, AL, Gamelin, L, Morel, A, et al.. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271–82. https://doi.org/10.1016/j.canlet.2006.09.006. Search in Google Scholar PubMed 4. HAS . Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine). [Internet]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2018-12/recherche_dun_deficit_en_dihydropyrimidine_deshydrogenase_visant_a_prevenir_certaines_toxicites_severes_associees_aux_traite.pdf. Search in Google Scholar 5. Maillard, M, Launay, M, Royer, B, Guitton, J, Gautier-Veyret, E, Broutin, S, et al., Groupe de Pharmacologie Clinique Oncologique (GPCO) . Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br J Clin Pharmacol 2023;89:762–72. https://doi.org/10.1111/bcp.15536. Search in Google Scholar PubMed PubMed Central 6. Heireman, L, Van Geel, P, Musger, L, Heylen, E, Uyttenbroeck, W, Mahieu, B. Causes, consequences and management of sample hemolysis in the clinical laboratory. Clin Biochem 2017;50:1317–22. https://doi.org/10.1016/j.clinbiochem.2017.09.013. Search in Google Scholar PubMed 7. Ingelse, B, Barroso, B, Gray, N, Jakob-Rodamer, V, Kingsley, C, Sykora, C, et al.. European Bioanalysis Forum: recommendation on dealing with hemolyzed and hyperlipidemic matrices. Bioanalysis 2014;6:3113–20. https://doi.org/10.4155/bio.14.252. Search in Google Scholar PubMed 8. Kuilenburg, ABPV, Lenthe, H, Blom, MJ, Mul, EPJ, Gennip, AHV. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 1999;79:620–6. https://doi.org/10.1038/sj.bjc.6690097. Search in Google Scholar PubMed PubMed Central © 2024 Walter de Gruyter GmbH, Berlin/Boston
medical laboratory technology